share_log

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Gibson Christopher

SEC announcement ·  Apr 5 17:49
Summary by Moomoo AI
Recursion Pharmaceuticals CEO Christopher Gibson completed a series of transactions involving the company's Class A Common Stock. On April 3 and 4, 2024, Gibson sold a total of 105,000 shares directly and indirectly through entities such as the Gibson Family Trust and LAHWRAN-3 LLC. The sales occurred at prices ranging from $8.84 to $9.02 per share, resulting in a total market value of $714,400 for the direct sales. After these transactions, Gibson directly holds 938,524 shares. Additionally, 50,000 shares were acquired indirectly by the Gibson Family Trust and LAHWRAN-3 LLC, which were then sold at similar price points, totaling $446,500 in market value. The transactions have been reported as completed.
Recursion Pharmaceuticals CEO Christopher Gibson completed a series of transactions involving the company's Class A Common Stock. On April 3 and 4, 2024, Gibson sold a total of 105,000 shares directly and indirectly through entities such as the Gibson Family Trust and LAHWRAN-3 LLC. The sales occurred at prices ranging from $8.84 to $9.02 per share, resulting in a total market value of $714,400 for the direct sales. After these transactions, Gibson directly holds 938,524 shares. Additionally, 50,000 shares were acquired indirectly by the Gibson Family Trust and LAHWRAN-3 LLC, which were then sold at similar price points, totaling $446,500 in market value. The transactions have been reported as completed.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more